Canada -
English -
Health Canada
apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
Canada -
English -
Health Canada
apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
Canada -
English -
Health Canada
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
Canada -
English -
Health Canada
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
Canada -
English -
Health Canada
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg
Canada -
English -
Health Canada
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg
Canada -
English -
Health Canada
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
Canada -
English -
Health Canada
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
European Union -
English -
EMA (European Medicines Agency)
rasagiline mylan
mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Ireland -
English -
HPRA (Health Products Regulatory Authority)
rasagiline accord
accord healthcare limited - rasagiline tartrate - tablets - 1 milligram - rasagiline - anti-parkinson-drugs, monoamine oxidase -b inhibitors - rasagiline accord is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.